These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 34673106)

  • 21. ACE2: The Major Cell Entry Receptor for SARS-CoV-2.
    Scialo F; Daniele A; Amato F; Pastore L; Matera MG; Cazzola M; Castaldo G; Bianco A
    Lung; 2020 Dec; 198(6):867-877. PubMed ID: 33170317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: A case study.
    Karakaş Çelik S; Çakmak Genç G; Pişkin N; Açikgöz B; Altinsoy B; Kurucu İşsiz B; Dursun A
    J Med Virol; 2021 Oct; 93(10):5947-5952. PubMed ID: 34170561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Putative mechanism of neurological damage in COVID-19 infection.
    Bandala C; Cortes-Altamirano JL; Reyes-Long S; Lara-Padilla E; Ilizaliturri-Flores I; Alfaro-Rodríguez A
    Acta Neurobiol Exp (Wars); 2021; 81(1):69-79. PubMed ID: 33949163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The key role of the level of ACE2 gene expression in SARS-CoV-2 infection.
    Lecarpentier Y; Vallée A
    Aging (Albany NY); 2021 Jun; 13(11):14552-14556. PubMed ID: 34115612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of ACE2 Polymorphisms on COVID-19 Disease: Susceptibility, Severity, and Therapy.
    Chen F; Zhang Y; Li X; Li W; Liu X; Xue X
    Front Cell Infect Microbiol; 2021; 11():753721. PubMed ID: 34746028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 spike protein binding selectively accelerates substrate-specific catalytic activity of ACE2.
    Kiseleva AA; Troisi EM; Hensley SE; Kohli RM; Epstein JA
    J Biochem; 2021 Oct; 170(2):299-306. PubMed ID: 33774672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interactions of renin-angiotensin system and COVID-19: the importance of daily rhythms in ACE2, ADAM17 and TMPRSS2 expression.
    Zlacká J; Stebelová K; Zeman M; Herichová I
    Physiol Res; 2021 Dec; 70(S2):S177-S194. PubMed ID: 34913351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2, ACE2 expression, and systemic organ invasion.
    Ashraf UM; Abokor AA; Edwards JM; Waigi EW; Royfman RS; Hasan SA; Smedlund KB; Hardy AMG; Chakravarti R; Koch LG
    Physiol Genomics; 2021 Feb; 53(2):51-60. PubMed ID: 33275540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Bound Human Serum Albumin and Systemic Septic Shock.
    Johnson AS; Fatemi R; Winlow W
    Front Cardiovasc Med; 2020; 7():153. PubMed ID: 33088822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 vulnerabilities are intensified by declining human serum albumin levels.
    Johnson AS; Winlow W
    Exp Physiol; 2022 Jul; 107(7):674-682. PubMed ID: 34275164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
    Kaushik P; Kaushik M; Parveen S; Tabassum H; Parvez S
    Mol Neurobiol; 2020 Dec; 57(12):4921-4928. PubMed ID: 32813238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study.
    Parit R; Jayavel S
    Eur J Pharmacol; 2021 Apr; 896():173899. PubMed ID: 33508281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased circulating microparticles contribute to severe infection and adverse outcomes of COVID-19 in patients with diabetes.
    Sun H; Du Y; Kumar R; Buchkovich N; He P
    Am J Physiol Heart Circ Physiol; 2022 Dec; 323(6):H1176-H1193. PubMed ID: 36269646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transfusion requirements in patients with COVID-19.
    Worrall AP; Kelly C; O'Neill A; Reidy N; O'Doherty M; Griffin L; Quinn J; Thornton P; Fitzpatrick F; Curley GF; Morgan R; Glavey S; McNally C; McConkey S; Murphy P; de Barra E; Lavin M
    Eur J Haematol; 2021 Jan; 106(1):132-134. PubMed ID: 32979865
    [No Abstract]   [Full Text] [Related]  

  • 38. ACE2: from protection of liver disease to propagation of COVID-19.
    Warner FJ; Rajapaksha H; Shackel N; Herath CB
    Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
    Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
    G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating Soluble ACE2 and Upstream microRNA Expressions in Serum of Type 2 Diabetes Mellitus Patients.
    Elemam NM; Hasswan H; Aljaibeji H; Sulaiman N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.